Home > Insider Trading > Filing (0001209191-18-039316)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1628738	Audentes Therapeutics Inc.	BOLD	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1416175	David Nagler	C/O Audentes Therapeutics, Inc. 600 California Street, 17Th Floor San Francisco CA 94108	Svp, Hr & Corp. Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-06-20	4,700	$2.19	4,700	No	4	M	Direct
Common Stock	Disposition	2018-06-20	4,700	$45.25	0	No	4	S	Direct
Common Stock	Acquisiton	2018-06-20	300	$2.19	300	No	4	M	Direct
Common Stock	Disposition	2018-06-20	300	$46.02	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2018-06-20	5,000	$0.00	5,000	$2.19

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
32,347		2025-02-04	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. The lowest price at which shares were sold was $45.00 and the highest price at which shares were sold was $45.97. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
Represents the weighted average sale price. The lowest price at which shares were sold was $46.00 and the highest price at which shares were sold was $46.06.
The option vested as to 25% of the total shares on February 1, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 1, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.